Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

21 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Do plasma concentrations of delta 9-tetrahydrocannabinol reflect the degree of intoxication?
Hollister LE, Gillespie HK, Ohlsson A, Lindgren JE, Wahlen A, Agurell S. Hollister LE, et al. Among authors: wahlen a. J Clin Pharmacol. 1981 Aug-Sep;21(S1):171S-177S. doi: 10.1002/j.1552-4604.1981.tb02593.x. J Clin Pharmacol. 1981. PMID: 6271822
It is unlikely that a range of plasma concentrations can be reliably equated with impaired performance. The mode of administration will become important should THC or some homolog become a therapeutic agent....
It is unlikely that a range of plasma concentrations can be reliably equated with impaired performance. The mode of administration wi …
Single dose kinetics of deuterium labelled delta 1-tetrahydrocannabinol in heavy and light cannabis users.
Ohlsson A, Lindgren JE, Wahlén A, Agurell S, Hollister LE, Gillespie HK. Ohlsson A, et al. Among authors: wahlen a. Biomed Mass Spectrom. 1982 Jan;9(1):6-10. doi: 10.1002/bms.1200090103. Biomed Mass Spectrom. 1982. PMID: 6277407
Thus, it seems likely that the statistically significant difference in systemic availability of smoked delta 1-tetrahydrocannabinol was due to a more efficient smoking by the heavy users. ...Based on the area under curve values after i.v. administration, a plasma cl …
Thus, it seems likely that the statistically significant difference in systemic availability of smoked delta 1-tetrahydrocannabinol was due …
Plasma delta-9 tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking.
Ohlsson A, Lindgren JE, Wahlen A, Agurell S, Hollister LE, Gillespie HK. Ohlsson A, et al. Among authors: wahlen a. Clin Pharmacol Ther. 1980 Sep;28(3):409-16. doi: 10.1038/clpt.1980.181. Clin Pharmacol Ther. 1980. PMID: 6250760
Oral THC in a chocolate cookie provided systemic availability of 6 +/- 3%. Of the two major clinical signs of cannabis intoxication, reddened conjunctivae persisted for as long as THC levels were above 5 ng/ml, and tachycardia was a less reliable measurement of prev …
Oral THC in a chocolate cookie provided systemic availability of 6 +/- 3%. Of the two major clinical signs of cannabis intoxication, …
Pharmacokinetics of raclopride formulations. Influence of prolactin and tolerability in healthy male volunteers.
Movin-Osswald G, Nordström AL, Hammarlund-Udenaes M, Wahlén A, Farde L. Movin-Osswald G, et al. Among authors: wahlen a. Clin Pharmacokinet. 1992 Feb;22(2):152-61. doi: 10.2165/00003088-199222020-00006. Clin Pharmacokinet. 1992. PMID: 1551292
Remoxipride--a new potential antipsychotic compound. Tolerability and pharmacokinetics after single oral and intravenous administration in healthy male volunteers.
Grind M, Nilsson MI, Nilsson L, Oxenstierna G, Sedvall G, Wahlén A. Grind M, et al. Among authors: wahlen a. Psychopharmacology (Berl). 1989;98(3):304-9. doi: 10.1007/BF00451679. Psychopharmacology (Berl). 1989. PMID: 2568653
An open label trial of raclopride in acute schizophrenia. Confirmation of D2-dopamine receptor occupancy by PET.
Farde L, Wiesel FA, Jansson P, Uppfeldt G, Wahlen A, Sedvall G. Farde L, et al. Among authors: wahlen a. Psychopharmacology (Berl). 1988;94(1):1-7. doi: 10.1007/BF00735871. Psychopharmacology (Berl). 1988. PMID: 3126517
The new selective D2-dopamine receptor antagonist raclopride--pharmacokinetics, safety and tolerability in healthy males.
Farde L, von Bahr C, Wahlen A, Nilsson L, Widman M. Farde L, et al. Among authors: wahlen a. Int Clin Psychopharmacol. 1989 Apr;4(2):115-26. doi: 10.1097/00004850-198904000-00003. Int Clin Psychopharmacol. 1989. PMID: 2526172 Clinical Trial.
Influence of alaproclate on antipyrine metabolite formation in man.
Teunissen MW, Wahlén A, Vinnars E, Breimer DD. Teunissen MW, et al. Among authors: wahlen a. Eur J Clin Pharmacol. 1984;27(4):447-52. doi: 10.1007/BF00549593. Eur J Clin Pharmacol. 1984. PMID: 6519152
21 results
Jump to page
Feedback